Novozymes Valuation
| NVZMY Stock | USD 58.24 0.78 1.32% |
At this time, the firm appears to be overvalued. Novozymes AS secures a last-minute Real Value of $51.2 per share. The latest price of the firm is $58.24. Our model forecasts the value of Novozymes AS from analyzing the firm fundamentals such as Profit Margin of 0.21 %, current valuation of 14.47 B, and Return On Equity of 0.28 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novozymes' price fluctuation is very steady at this time. Calculation of the real value of Novozymes AS is based on 3 months time horizon. Increasing Novozymes' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Novozymes is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novozymes Pink Sheet. However, Novozymes' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.24 | Real 51.2 | Hype 58.24 | Naive 59.62 |
The intrinsic value of Novozymes' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novozymes' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novozymes AS helps investors to forecast how Novozymes pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novozymes more accurately as focusing exclusively on Novozymes' fundamentals will not take into account other important factors: Novozymes Total Value Analysis
Novozymes AS is now expected to have takeover price of 14.47 B with market capitalization of 14.41 B, debt of 7.31 B, and cash on hands of 1.01 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novozymes fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.47 B | 14.41 B | 7.31 B | 1.01 B |
Novozymes Investor Information
The company last dividend was issued on the 6th of March 2023. Novozymes AS had 5:1 split on the 9th of December 2011. Based on the key indicators related to Novozymes' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Novozymes AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Novozymes Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novozymes has an asset utilization ratio of 62.73 percent. This suggests that the Company is making $0.63 for each dollar of assets. An increasing asset utilization means that Novozymes AS is more efficient with each dollar of assets it utilizes for everyday operations.Novozymes Profitability Analysis
The company reported the revenue of 17.55 B. Net Income was 3.69 B with profit before overhead, payroll, taxes, and interest of 9.59 B.About Novozymes Valuation
Our relative valuation model uses a comparative analysis of Novozymes. We calculate exposure to Novozymes's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novozymes's related companies.Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novozymes Unspn is traded on OTC Exchange in the United States.
8 Steps to conduct Novozymes' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novozymes' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novozymes' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novozymes' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novozymes' revenue streams: Identify Novozymes' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novozymes' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novozymes' growth potential: Evaluate Novozymes' management, business model, and growth potential.
- Determine Novozymes' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novozymes' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Novozymes Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 278.7 M | |
| Quarterly Earnings Growth Y O Y | 0.42 | |
| Forward Price Earnings | 29.3255 | |
| Retained Earnings | 13.1 B |
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.